SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a
clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast
conditions, today announced it will host a corporate conference call to discuss the Company’s business on Wednesday, May 16, 2018
at 4:30 EDT. The call is being provided so that stockholders and potential investors can hear directly from senior management about
the Company’s business with a focus on recent developments.
Due to expected high call attendance, participants are asked to preregister for the call through the following link: http://dpregister.com/10120189. Please note that registered participants will receive their dial
in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to
pre-register may dial in by calling: 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll Free:
1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call.
The conference call will also be available through a live webcast through the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar or through the following link: https://services.choruscall.com/links/atos180507.html.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary
rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under
development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com
Source: Atossa Genetics Inc.
![Primary Logo](https://resource.globenewswire.com/Resource/Download/25b79114-0ca0-4348-a136-9afce33e910d?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzI2Njk0NA==)